Xanthine oxidase and cardiovascular risk in obese children

Childhood Obesity

Volumn 10, Issue 2, 2014, Pages 175-180

  Tam, Harrison K ^a   Kelly, Aaron S ^b   Metzig, Andrea M ^b   Steinberger, Julia ^b   Johnson, L'Aurelle A ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

XANTHINE OXIDASE;

ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; CHILDHOOD OBESITY; COMPLICATION; DIET RESTRICTION; FEMALE; HUMAN; MALE; METABOLISM; OXIDATIVE STRESS; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; FASTING; FEMALE; HUMANS; MALE; OXIDATIVE STRESS; PEDIATRIC OBESITY; RISK FACTORS; XANTHINE OXIDASE;

EID: 84898036895     PISSN: 21532168     EISSN: 21532176     Source Type: Journal    
DOI: 10.1089/chi.2013.0098     Document Type: Article

References (28)

1. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012;82:1-8
2. Freedman DS, Mei Z, Srinivasan SR, et al. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: The Bogalusa Heart Study. J Pediatr 2007;150:12-17.e2
3. Montezano A, Touyz R. Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: A basic science update for the clinician. Can J Cardiol 2012;28:288-295
4. Paravicini T, Touyz R. NADPH oxidases, reactive oxygen species, and hypertension: Clinical implications and therapeutic possibilities. Diabetes Care 2008;31(Suppl 2):S170-S180
5. Guthikonda S, Sinkey C, Barenz T, et al. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003;107:416-421
6. Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000;35:746-751
7. Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: A systematic review and meta-Analysis. 2012;30:217-226
8. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: Methods and development. Vital Health Stat 11 2002;246:1-190
9. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
10. Kelly A, Jacobs D, Sinaiko A, et al. Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatr Diabetes 2010;11:552-555
11. Nyberg G, Ekelund U, Yucel Lindberg TL, et al. Differences in metabolic risk factors between normal weight and overweight children. Int J Pediatr Obes 2011;6:244-252
12. Huang R, de Klerk N, Mori T, et al. Differential relationships between anthropometry measures and cardiovascular risk factors in boys and girls. Int J Pediatr Obes 2011;6:e271-e282
13. Chiney MS, Schwarzenberg SJ, Johnson LA. Altered xanthine oxidase and N-Acetyltransferase activity in obese children. Br J Clin Pharmacol 2011;72:109-115
14. Kong APS, Choi KC, Ho CS, et al. Associations of uric acid and gamma-glutamyltransferase (GGT) with obesity and components of metabolic syndrome in children and adolescents. Pediatr Obes 2013;8:351-357
15. Ford ES, Li C, Cook S, et al. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007;115:2526-2532
16. Pacifico L, Cantisani V, Anania C, et al. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur J Endocrinol 2009;160:45-52
17. Chedid R, Zoghbi F, Halaby G, et al. Serum uric acid in relation with the metabolic syndrome components and adiponectin levels in Lebanese University students. J Endocrinol Invest 2011;34:e153-e157
18. Tsioufis C, Kyvelou S, Dimitriadis K, et al. The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. J Hum Hypertens 2011;25:554-559
19. Tamba S, Nishizawa H, Funahashi T, et al. Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med 2008;47: 1175-1180
20. Bo S, Gambino R, Durazzo M, et al. Associations between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction. J Endocrinol Invest 2008;31:499-504
21. Xing L, Remick DG. Mechanisms of oxidant regulation of monocyte chemotactic protein 1 production in human whole blood and isolated mononuclear cells. Shock 2007;28:178-185
22. Codoner-Franch P, Tavarez-Alonso S, Murria-Estal R, et al. Nitric oxide production is increased in severely obese children and related to markers of oxidative stress and inflammation. Atherosclerosis 2011;215:475-480
23. Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106:221-226
24. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 2002;105:2619-2624
25. Chander R, Kapoor NK. High density lipoprotein is a scavenger of superoxide anions. Biochem Pharmacol 1990;40:1663-1665
26. Norris A, Steinberger J, Steffen L, et al. Circulating oxidized LDL and inflammation in extreme pediatric obesity. Obesity (Silver Spring) 2011;19:1415-1419
27. Kato R, Mori C, Kitazato K, et al. Transient increase in plasma oxidized LDL during the progression of atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2009; 29:33-39
28. Tsimikas S, Aikawa M, Miller FJ, et al. Increased plasma oxidized phospholipid: Apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: A potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol 2007; 27:175-181.